NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

March 05, 2020

Michael L. Grossbard, MD, discusses the utility of PI3K inhibitors in follicular lymphoma.

March 05, 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the effects ruxolitinib has on symptom burden in patients with myeloproliferative neoplasms.

March 05, 2020

Faith E. Davies, MD, discusses pivotal research in relapsed/refractory myeloma and precision medicine efforts in the field.

March 04, 2020

Michael L. Grossbard, MD, discusses recent changes to the follicular lymphoma paradigm and therapeutic approaches on the horizon.

March 04, 2020

Arjun V. Balar, MD, discusses how immunotherapy options are helping to reduce reliance on platinum chemotherapy and cystectomy, as well as further efforts to engage the immune system in the fight against bladder cancer and other pathways toward greater treatment efficacy and quality of life for patients.

March 04, 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses some of the current and investigational treatment options for patients with myeloproliferative neoplasms.

March 03, 2020

Bruce G. Raphael, MD, discusses the treatment landscape of chronic lymphocytic leukemia.

February 28, 2020

Tracey Liebman, MD, discusses the use of digital surveillance in melanoma.

February 28, 2020

Richard L. Shapiro, MD, discusses the surgical management of advanced-stage melanoma.

February 19, 2020

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

February 18, 2020

Julia Fehniger, MD, discusses emerging strategies in the treatment paradigm for patients with BRCA1/2-mutant endometrial cancer.

February 14, 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses the nuances of immunotherapy related adverse events in melanoma.

February 13, 2020

Diane M. Simeone, MD, discusses the impact of PARP inhibitors on pancreatic cancer.

February 12, 2020

In our exclusive interview, Jeffrey S. Weber, MD, PhD, shares with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.

January 31, 2020

Tracey Liebman, MD, discusses the toxicities associated with BRAF inhibitors in melanoma.

January 30, 2020

David Polsky, MD, PhD, discusses the exploration of blood-based biomarkers in melanoma.

January 28, 2020

Richard L. Shapiro, MD, discusses the evolution and current role of surgery in advanced melanoma.

January 27, 2020

Francisco J. Esteva, MD, PhD, discusses how the use of precision medicine has helped improve the treatment of patients with breast cancer.

January 27, 2020

Jeffrey S. Weber, MD, PhD, discusses adjuvant approaches in stage III melanoma.

January 27, 2020

Anna C. Pavlick, DO, discusses the importance of immunotherapy for patients with metastatic melanoma.